Stock Research: Cosmo Pharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Cosmo Pharmaceuticals

SWX:COPN NL0011832936
96
  • Value
    92
  • Growth
    25
  • Safety
    Safety
    63
  • Combined
    73
  • Sentiment
    100
  • 360° View
    360° View
    96
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Cosmo Pharmaceuticals N.V. is a pharmaceutical company focused on gastrointestinal diseases, dermatology, and healthtech. It operates in the pharmaceutical industry and its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, GI Genius, Eleview, Aemcolo, Methylene Blue MMX, and Winlevi. In the last fiscal year, the company had a market cap of $1,357 million, profits of $229 million, and revenue of $276 million, with 322 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 96 (better than 96% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Cosmo Pharmaceuticals are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Cosmo Pharmaceuticals. The consolidated Value Rank has an attractive rank of 63, which means that the share price of Cosmo Pharmaceuticals is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 63% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 92. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 100. But the consolidated Growth Rank has a low rank of 25, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 75 of its competitors have better growth. ...read more

more
Index
SPI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
63 34 57 32
Growth
25 45 77 33
Safety
Safety
92 54 30 47
Sentiment
100 94 100 74
360° View
360° View
96 67 94 36
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
97 87 100 95
Opinions Change
73 50 83 50
Pro Holdings
n/a 96 80 60
Market Pulse
85 57 53 21
Sentiment
100 94 100 74
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
63 34 57 32
Growth
25 45 77 33
Safety Safety
92 54 30 47
Combined
73 43 62 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
33 75 46 5
Price vs. Earnings (P/E)
9 13 18 7
Price vs. Book (P/B)
63 59 67 85
Dividend Yield
88 1 70 57
Value
63 34 57 32
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
94 8 88 8
Profit Growth
8 100 98 100
Capital Growth
38 33 15 44
Stock Returns
11 45 38 22
Growth
25 45 77 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
94 95 46 39
Refinancing
51 43 39 78
Liquidity
100 24 29 19
Safety Safety
92 54 30 47

Similar Stocks

Discover high‑ranked alternatives to Cosmo Pharmaceuticals and broaden your portfolio horizons.

thyssenkrupp

XTRA:TKA
Country: Germany
Industry: Steel
Size: X-Large
Full Stock Analysis

RTL Group

XTRA:RRTL
Country: Luxembourg
Industry: Broadcasting
Size: Large
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Polski Koncern Naftowy ORLEN Spolka Akcyjna

WSE:PKN
Country: Poland
Industry: Oil & Gas Refining
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.